why choose us

First received: September 17, 2023

Clinical Trial: A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Idiopathic Pulmonary Fibrosis

Study Type: INTERVENTIONAL


Official Title: A Multi-center, Randomized, Double-Blinded, Parallel and Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy in Idiopathic Pulmonary Fibrosis (IPF)

Brief Summary: Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues.REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment.This is a multi-center, randomized, double-blinded, parallel and placebo-controlled phase II clinical study to evaluate the efficacy and safety of REGEND001 in IPF patients.

Read more